Current Oncology, Free Full-Text
4.8 (450) · $ 8.00 · In stock
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.
News: Is Relatively Pain-free Cancer Treatment Now Possible?
Radiation Oncology CME/CE Continuing Medical Education Courses
First-line Atezolizumab Monotherapy Versus Single-agent, 43% OFF
Current Oncology 2023 - Browse Issues
Urologic Oncology: Seminars and Original Investigations, Journal
New Cardio-Oncology Resources Page on - American College
Current Oncology, Free Full-Text
UQOnc
PDF) Corrigendum: Progression-Free Survival in Advanced Ovarian
Oncology 1971: Vol 25 Index : Free Download, Borrow, and Streaming
Current Oncology, Free Full-Text
